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The absorption of oral morroniside in rats: 
In vivo, in situ and in vitro studies
Morroniside is one of the most important iridoid glyco-
sides from Cornus officinalis Sieb. et Zucc. In the present 
study, the pharmacokinetics and bioavailability studies of 
morroniside were conducted on Sprague-Dawley (SD) 
rats. A rat in situ in testi nal perfusion model was used to 
characterize the absorp tion of morroniside. Caco-2 cells 
were used to examine the transport mechanisms of morro-
niside. The pharmacokinetic study of morroniside ex hi-
bited linear dose-proportional pharmaco kinetic charac-
teristics and low bioavailability (4.3 %) in SD rats. Its 
average Peff value for transport across the small intestinal 
segments changed from (3.09 ± 2.03) × 10–6 to (4.53 ± 0.94) × 
10–6 cm s–1. In Caco-2 cells, the Papp values ranged from 
(1.61 ± 0.53) × 10–9 to (1.19 ± 0.22) × 10–7 cm s–1 for the apical 
to basolateral side and the Pratio values at three concentra-
tions were all lower than 1.2. Morroniside showed poor 
ab sorption and it might not be a specific substrate of P-glyco-
protein (P-gp).
Keywords: morroniside, pharmacokinetics, absorption, 
rats, in situ single-pass intestinal perfusion, Caco-2 cell
Morroniside, one of the most important iridoid glycosides, is the main active ingredi-
ent of Cornus officinalis Sieb. et Zucc. It is a rich source of iridoid glycosides and has been 
used as a traditional Chinese medicinal herb for centuries (1). Various pharmacological 
studies have indicated that morroniside was effective in the treatment of Alzheimer’s dis-
ease (2) for protecting nerves (3), preventing diabetic liver damage (4) and renal damage 
(5), having beneficial effects on lipid metabolism and inflammation (6, 7) and anti-anaphy-
lactic activity (8). In recent studies, morroniside displayed protective actions against the 
cytotoxicity produced by exposure to H2O2 in human SH-SY5Y cells (9, 10). In addition, 
morroniside could protect ischemia/reperfusion-induced brain injury by decreasing cas-
pase-3 activity, reducing the infarction volume, minimizing oxidative stress, etc. (11). Sev-
eral research papers have been published on the pharmacological activity of ingredients 
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essential. Pharmacokinetic profiles help elaborate the relationship between the intensity 
and time course of pharmacological events, the in vivo toxicological effects of ingredients, 
and extend the scope of the use and acceptance of different species (12).
In our previous work, the analytical methods for determination of morroniside in rat 
plasma and beagle dog plasma using LC-MS/MS were reported (13, 14). In addition, the 
excretion profile of morroniside in rats was investigated by a validated LC-MS/MS method 
(15).
Thus far, no research was done on the absorption kinetics of morroniside. In the pres-
ent study, the absorption of oral morroniside was systematically investigated, in vivo, in situ 
and in vitro. The key absorption issues mentioned are addressed in support of the develop-
ment of morroniside as a candidate drug.
EXPERIMENTAL
Chemicals
Morroniside (purity > 98.5 %) was extracted and purified in the Department of Phar-
macology, Xuanwu Hospital of Capital Medical University (China). Hyperoside (IS) was 
purchased from the National Institute for the Control of Pharmaceutical and Biological 
Products (China). LC-MS grade methanol and acetonitrile were obtained from Thermo 
Fisher Scientific (USA). All other reagents were of analytical grade or better.
Non-essential amino acid solution (100×) and DMEM (high glucose) medium were 
purchased from Thermo Fisher Scientific. Fetal bovine serum was supplied by Biological 
Industries (Israel). N-[2-hydroxyethyl] piperazine-N’-[4-butanesulfonic acid], penicillin 
and streptomycin solutions, and geneticin were obtained from Amresco (USA).
Pharmacokinetic studies
Twenty healthy male Sprague-Dawley (SD) rats (weighing 180–220 g, n = 5 per group) 
were used for pharmacokinetic studies. They were purchased from the Beijing Institute of 
Pharmacology and Toxicology (China). Rats housed in polypropylene cages were kept under 
controlled temperature (20–22 °C) and a 12-h day-night cycle. Animals were used for 
pharma co kinetic studies after 1-week acclimatization with food and water provided ad libitum.
Animal welfare and experimental procedures were approved by the Animal Ethics 
Committee of the Institute of Materia Medica, Shandong Academy of Medical Sciences 
(Jinan, China), and strictly complied with the guide for the care and use of laboratory 
animals (National Research Council of USA, 1996).
Jugular vein catheterization was performed as described previously (16). For bioavail-
ability study, one group of rats was administered an intravenous dose (10 mg kg–1 via the 
tail vein) of morroniside. For oral pharmacokinetic studies, three groups of rats were ad-
ministered an oral dose of 10, 30 and 90 mg kg–1 of morroniside, resp. Blood samples (150 
µL) were collected from the jugular vein into heparinized tubes before and at 2, 5, 15, 30, 
45, 60, 120, 240, 360, 480 and 720 min after single i.v. dosing and 5, 15, 30, 45, 60, 120, 240, 
360, 480 and 720 min after single oral dosing. Samples were centrifuged at 3500 rpm for 15 
min at 4 °C and kept frozen at –20 °C prior to LC-MS/MS analysis.
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Pharmacokinetic parameters for morroniside were calculated by the Drug and Statistic 
(DAS) 2.0 pharmacokinetic software (Chinese Pharmacological Association, Anhui, 
China). F(0-∞) (%) was calculated by the following equation 1:





















In situ permeability studies
Forty-eight healthy male SD rats (180–220 g, n = 4) were used for the in situ single-pass 
perfusion study. Rats were anesthetized via an intraperitoneal injection of 1 % pentobarbital 
sodium (40 mg kg–1) and placed in a professional medical incubator to maintain the body 
temperature at 37 °C. The abdominal cavity was opened by a medioventral line incision, 
and approximately 10 cm of the duodenum, jejunum, ileum and colon segments were 
isolated carefully. The intestinal segment was intubated with a pliable plastic pipe at two 
ends and infused with Krebs-Ringer buffer (7.8 g NaCl, 0.35 g KCl, 0.37 g CaCl2, 1.37 g 
NaHCO3, 0.32 g NaH2PO4, 0.02 g MgCl2, 1.4 g glucose and 20 mg phenol red dissolved in 
1000 mL distilled water with pH adjusted to 7.4) for 10 min with the flow rate set at 1.0 mL 
min–1 using a single channel micro-infusion pump (WZ-50C66T, Smiths Medical Instru-
ment, China). Subsequently, Krebs-Ringer buffer containing 15, 30 and 60 µg mL–1 mor-
roniside was poured into the intestinal segment at a persistent flow rate of 0.2 mL min–1 
for about 1.5 h. Perfusion fluid samples gained from the outlet of intestinal segments were 
gathered every 15 min after equilibration for 30 min.
During the whole experiment, the exposed intestinal segments were maintained 
moist after cannulation with isotonic 0.9 % NaCl solution-moistened gauze and were kept 
at 37 °C. After in situ permeability studies, the radius and length of the duodenum, jeju-
num, ileum and colon segments were gauged (17).
Cout(corr) (µg mL–1, corrected outlet concentration of morroniside) and Peff (cm s–1, 
quantitative measure of the rate of morroniside permeability across the biomembrane) 














            (3)
where Cout (µg mL–1) is the uncorrected outlet concentration of morroniside, PRin and PRout 
(mg mL–1) are the inlet and outlet concentrations of phenol red, resp., Q (0.2 mL min–1) is 
the flow rate of the perfusate entering the rats’ isolated intestinal segments, Cout(corr) and 
Cin are the corrected outlet and inlet concentrations of morroniside, resp., r (cm) and L (cm) 
are the radius and length of the perfused intestinal segment.
Cell culture
Caco-2 cells (American Type Culture Collection, USA) between passage 40 and 50 
were used and cultured at 37 °C in 5 % CO2 at 90 % humidity in DMEM (high glucose) 
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medium containing 15 % fetal bovine serum, 1 % non-essential amino acid solution, 100 U 
mL–1 penicillin and 1 % streptomycin. The DMEM medium was replaced twice a week. The 
cells were seeded in collagen-coated transwell inserts (0.4-µm pore size, 24-mm diameter; 
Millipore, USA) at a density of 3 × 105 cells per insert. The cells were cultured for 21 days 
after seeding. The DMEM medium was replaced every two days.
Cytotoxicity test
The cytotoxicity test of morroniside to Caco-2 cells was performed using the MTT assay. 
The Caco-2 cells in the logarithmic growth phase were seeded onto a 96-well plate at a 
density of 1 × 105 cells per well in 100 µL DMEM culture medium. After culturing at 37 °C 
in 5 % CO2 for 3 days, the culture medium was replaced with 100 µL of morroniside solu-
tion in HBSS (pH 7.4) at concentrations of 6.4, 32, 160, 800 and 4000 µmol L–1 and the HBSS 
(pH 7.4) was used as a blank control. Two hundred (200) µL of 5 mg mL–1 MTT solution in 
HBSS was added to each well after the plate was incubated at 37 °C for 4 h, and then the 
plate was incubated for another 4 h. The medium was then replaced with 100 µL of DMSO. 
The absorbance of the mixture in the 96-well plate was measured at 570 nm. The cytotoxicity 
of morroniside at different concentrations was calculated by the percentage of absorbance 
relative to that of the blank control.
Transport studies
Only cultures with transepithelial electrical resistance (TEER) (Millicell ERS®, Milli-
pore) values over 400 Ω cm–2 were employed for the flux experiment. Before the experi-
ments, the Caco-2 cell monolayers were washed twice with incubation medium (HBSS, pH 
7.4, 137 mmol L–1 NaCl, 5.36 mmol L–1 KCl, 0.952 mmol L–1 CaCl2, 0.812 mmol L–1 MgSO4, 
0.440 mmol L–1 KH2PO4, 0.385 mmol L–1 Na2HPO4, 25 mmol L–1 D-glucose and 25 mmol L–1 
Hepes). Volumes of drug solution added to the apical (AP) and basolateral (BL) sides of the 
monolayer were 0.4 mL and 1.2 mL, resp. The permeability of morroniside (16, 80 and 400 
µmol L–1) under all the above conditions for both directions, from the AP-to-BL side and 
from the BL-to-AP side, was measured at 37 °C. A 50-µL aliquot of this incubation solution 
was withdrawn from the receiver compartment at 0, 15, 60 and 120 min.




















            (5)
where ΔQ/Δt (µmol s–1) is the permeation rate of morroniside, A (cm2) is the surface area of 
the epithelium (0.33 cm2) and C0 (µmol L–1) is the initial donor concentration of morroniside 
on the loading side. The Pratio of morroniside was obtained by dividing the BL→AP 
permeability by the AP→BL permeability.
Determination of morroniside by HPLC-MS/MS
The LC-MS/MS method has been already validated for the determination of morroni-
side in rat plasma over a concentration range of 2.0–5000 ng mL–1 with a lower limit of 
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quantification (LLOQ) of 2.0 ng mL–1 (13). Chromatographic separation was carried out on 
an Inertsil C8-3 column using acetonitrile and water containing 1 mmol L–1 sodium formate 
at 0.4 mL min–1 for 6 min. Linear gradient elution was applied. No interferences from endo-
genous substances were found at the retention times of either morroniside or IS. The intra- 
and inter-day accuracy for morroniside ranged from 91.4 to 98.2 % and 93.4 to 102.0 %, resp. 
Intra- and inter-day RSD for morroniside ranged from 4.3 to 5.1 % and 5.0 to 7.7 %.
Data acquisition was performed using an API 5000 triple-quadrupole mass spectro-
meter coupled with an ESI source (Applied Biosystems/MDS SCIEX, USA) and Analyst 
software (version 1.5.1). The ESI source was operated with ion spray voltage of 5000 V and 
heater temperature of 550 °C. Gas settings were as follows: curtain gas 15 L h–1, collision 
gas 5 L h–1, ion source gas 1: 30 L h–1, and ion source gas 2: 40 L h–1. Quantification was car-
ried out by multiple reaction monitoring (MRM) in a positive ionization mode. Hyperoside 
was used as an internal standard (IS). Transitions selected for quantification were m/z 
429→267 for morroniside and m/z 487→324 for IS. Collision energy values for morroniside 
and IS were 35 and 40 V, respectively.
Biosample preparation
Frozen biosamples were thawed at room temperature and vortex-mixed. Fifty µL of 
biosample was mixed with 50 µL water, 100 µL IS working solution (500 ng mL–1) and 150 
µL methanol and vortex-mixed for 1 min. After centrifugation at 14000 rpm at 4 °C for 10 
min, 10 µL of supernatant was injected onto the LC-MS/MS system for analysis (13).
Statistical analysis
Experimental data were expressed as mean ± standard deviation (SD). Statistical 
analysis was performed with the SPSS 20.0 software package (SPSS Inc., Chicago, IL, USA). 
Differences between the two groups were calculated by Student’s t test. Significance of the 
differences between groups for continuous variables was evaluated with one-way analysis 
of variance (ANOVA), the mA value of p < 0.05 indicating statistical significance.
RESULTS AND DISCUSSION
In vivo permeability of morroniside
The LC-MS/MS method was successfully applied to the pharmacokinetic studies of 
morroniside at doses of 10 (i.v. and p.o.), 30 (p.o.), and 90 (p.o.) mg kg–1 in rats. The pharmaco-
kinetics of morroniside in rats within the used dosage ranges (10, 30 and 90 mg kg–1) after 
oral administration was in accord with linear pharmacokinetic characteristics. The linear 
regression equation between AUC(0−t) and the dose was y = 58.98x – 249.02 (R2 = 0.9827), while 
it was y = 19.77x + 87.65 (R2 = 0.9958) between Cmax and the dose. Moreover, no apparent dif-
ferences for MRT, T1/2z, Tmax, Vd and CLz/F were observed regardless of increasing doses.
The AUC(0-t) of morroniside after an intravenous dose (10 mg kg–1) to SD rats was 
14673.84 ± 3512.36 ng h mL–1, compared with 610.84 ± 361.61, 1160.42 ± 412.12 and 5149.45 ± 
3557.32 ng h mL–1 after an oral dose of 10, 30, 90 mg kg–1 of morroniside, resp. The pharmaco-
kinetic study of morroniside within the used dosage ranges exhibited linear dose-proportional 
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pharmacokinetic characteristics and low bioavailability (4.3 %) in SD rats, which meant 
that only 4.3 % of the prototype drug was absorbed into blood circulation. The plasma 
concentration-time profiles of morroniside after intravenous and oral administration of 
morroniside to rats are shown in Figs. 1a,b with the corresponding pharmacokinetic 
parameters given in Table I.
In situ permeability of morroniside
This was the first study to investigate the absorption mechanism of morroniside using 
a single-pass intestinal perfusion in situ model in SD rats. The stability of morroniside in 
Fig. 1. Plasma concentration-time profiles of morroniside following: a) a single intravenous injection, 
and b) a single oral administration in rats (SD bars, n = 5).
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Krebs-Ringer buffer at 37 °C was investigated for at least 24 h, which showed that mor-
roniside was stable under the above conditions (data not published). Its average effective 
permeability coefficient (Peff value) for transport across the small intestinal segments 
changed from (3.09 ± 2.03) × 10–6 to (4.53 ± 0.94) × 10–6 cm s–1. The Peff values were basically 
consistent irrespective of increasing concentrations of morroniside at the measured con-
centrations from 15 to 60 µg mL–1 after perfusion via duodenum, jejunum, ileum and colon 
segments (Table II). The Peff values were all close to 3.0 × 10–6, which meant poor intestinal 
absorption (18) at three concentrations (15, 30, and 60 µg mL–1).
Bi-directional transport of morroniside across Caco-2 cells
The in vitro study investigated the bi-directional transport of morroniside across 
Caco-2. The MTT assay was used to investigate morroniside cytotoxicity to Caco-2 cells in 
order to establish appropriate practical concentrations for bi-directional transport re-
search. The result indicated that morroniside showed no toxic effect to Caco-2 cells in the 
Table I. Pharmacokinetic parameters of morroniside in rats
Parameter
Treatment (mg kg–1)a
10 (i.v.) 10 (p.o.) 30 (p.o.) 90 (p.o.)
AUC(0-t) (ng h mL–1) 14673.84 ± 3512.36 610.84 ± 361.61 1160.42 ± 412.12 5149.45 ± 3557.32
AUC(0-∞) (ng h mL–1) 14688.29 ± 3509.75 628.86 ± 356.95 1191.68 ± 465.35 5215.45 ± 3610.10
MRT(0-t) (h) 0.38 ± 0.08 1.62 ± 0.49 1.43 ± 0.27 1.90 ± 0.58
T1/2z (h) 1.77 ± 0.35 1.26 ± 0.65 1.40 ± 1.17 1.24 ± 0.37
Tmax (h) 0.03 ± 0.00 1.00 ± 0.00 0.57 ± 0.34 1.05 ± 0.57
CLz (L h–1 kg–1) 0.71 ± 0.17 19.82 ± 9.02 27.59 ± 7.89 27.23 ± 19.45
Vz (L kg–1) 1.88 ± 0.76 36.86 ± 31.27 49.61 ± 35.04 47.95 ± 39.07
Cmax (ng mL–1) 46530.00 ± 5238.63 329.60 ± 168.27 621.80 ± 227.07 1881.80 ± 881.34
F(0-∞) (%) – 4.3 – –
a Mean ± SD, n = 5.
Table II. The Peff values of three concentrations of morroniside in different intestinal segments
Morroniside 
(µg mL–1)
Peff value × 106 (cm s–1)a
Duodenum Jejunum Ileum Colon
15 3.11 ± 1.71 3.63 ± 1.48 3.31 ± 1.98 3.09 ± 2.03
30 4.30 ± 2.15 3.96 ± 1.23 4.53 ± 0.94 4.31 ± 1.80
60 4.46 ± 1.52 4.13 ± 1.78 4.42 ± 1.73 4.28 ± 1.64
a Mean ± SD, n = 4.
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concentration range from 6.4 µmol L–1 to 4.0 mmol L–1. Morroniside concentrations (16, 80, 
and 400 µmol L–1) were used to investigate the morroniside transport mechanism across 
the Caco-2 cell monolayer, which showed that the apparent permeability coefficient (Papp) 
values of morroniside ranged from (1.61 ± 0.53) × 10–9 to (1.19 ± 0.22) × 10–7 cm s–1 for AP to 
BL. The efflux ratios (Pratio) at three concentrations were all lower than 1.2.
It could be inferred that the active uptake transport was involved in the absorption 
process of morroniside, because the Pratio values decreased with the increase in morroni-
side concentration. In addition, according to the obtained Pratio values from all concentra-
tions and time points (Pratio value < 1.5), it could be concluded that morroniside might not 
be a substrate for P-gp (19), but active uptake transports might be involved in the transport 
of morroniside across the Caco-2 cell monolayer. The impact of time on morroniside ab-
sorption at the above concentrations is presented in Fig. 2. The Pratio values of morroniside 
are summarized in Table III.
Fig. 2. Impact of time and concentration on morroniside absorption (SD bars, n = 3).
Table III. The Pratio of morroniside
t (min)
Pratio at morroniside concentrationa
16 (µmol L–1) 80 (µmol L–1) 400 (µmol L–1)
15 0.01 0.01 0.6
60 0.04 0.3 1.2
120 0.05 0.5 1.2
a Mean value, n = 3.
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CONCLUSIONS
In conclusion, the present research studied in vivo, in situ, and in vitro absorption of oral 
morroniside. The pharmacokinetics of morroniside in rats within the used dosage ranges 
exhibited linear dose-proportional pharmacokinetic characteristics and low bioavailability. 
The in situ and in vitro results indicated that the intestinal transport of morroniside obeyed 
a concentration-independent active transport mechanism and the P-gp was not involved in 
morroniside transport. This research provided a rational explanation for the poor absorp-
tion of morroniside observed in pharmacokinetic experiments. For the above reasons, fur-
ther investigations would be required to improve morroniside bioavailability.
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Acronyms, abbreviations, symbols. – A – surface area of the epithelium, AP – apical side, AUC – area 
under curve, BL – basolateral side, C0 – initial donor concentration on the loading side, CLz – clearance, 
Cmax – peak concentration, Cout – uncorrected outlet concentration, Cin – corrected inlet concentration, 
Cout(corr) – corrected outlet concentration, ΔQ/Δt – permeation rate, DMEM – Dulbecco’s modified Eagle 
medium, F – bioavailability, HBSS – Hank’s balanced salt solution, L – length of the perfused intestinal 
segment, MRM – multiple reaction monitoring, MRT – mean residence time, Papp – apparent 
permeability coefficient values, MTT – 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium 
bromide, Peff – rate of permeability across a membrane, P-gp – P-glycoprotein, PRin – inlet concentration 
of phenol red, PRout – outlet concentration of phenol red, Q – perfusion flow rate through the intestinal 
segment, r – radius of the perfused intestinal segment, SD rats – Sprague Dawley rats, T1/2z – half-life, 
TEER – transepithelial electrical resistance, Tmax – peak time, Vz – apparent volume of distribution.
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